Replimune (REPL) Research & Development (2017 - 2025)

Replimune has disclosed Research & Development across 9 years of filings, most recently posting $53.1 million for Q4 2025.

• Research & Development for Q4 2025 came in at $53.1 million, up 10.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $222.8 million (up 25.89% YoY), and the FY2025 annual result was $189.4 million, up 8.28% from the prior year.
• Research & Development came in at $53.1 million for Q4 2025 at Replimune, down from $57.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $57.9 million in Q3 2025 to a low of $16.2 million in Q1 2021.
• The 5-year median for Research & Development is $41.5 million (2023), against an average of $37.7 million.
• Across the five-year window, Research & Development jumped 74.61% in 2023 and dropped 11.51% in 2024, its largest moves.
• Replimune's Research & Development stood at $19.4 million in 2021, then soared by 56.36% to $30.3 million in 2022, then soared by 41.59% to $42.8 million in 2023, then advanced by 12.04% to $48.0 million in 2024, then grew by 10.7% to $53.1 million in 2025.
• The last three Research & Development figures came in at $53.1 million (Q4 2025), $57.9 million (Q3 2025), and $57.8 million (Q2 2025), per Business Quant data.